Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present PURE Bioscience (OTC: PURE).

Full DD Report for PURE

You must become a subscriber to view this report.


Recent News from (OTC: PURE)

Daily Insider Ratings Round Up 8/20/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: August, 22 2018 15:46
PURE Bio secures $1.5M capital raise
PURE Bioscience (NASDAQ: PURE ) has closed a private offering of ~3.3M shares of common stock at $0.45 per share with existing investors. The company says the amount raised includes the forgiveness of $504K in debt held by a director. More news on: PURE Bioscience, Healthcare stocks news...
Source: SeekingAlpha
Date: August, 16 2018 16:32
PURE Bioscience Closes on $1.5 Million Financing and Provides Business Update
PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, announced today that it has closed on an approximately $1.5 million private placement with existing shareholders. The $1.5 million the company raised includes cancelled i...
Source: Business Wire
Date: August, 16 2018 16:10
PURE Bioscience Raises $500,000 in Unsecured Promissory Note - Appoints Ivan Chen to Board of Directors
PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today announced that it has raised $500,000 in the form of a promissory note from Tom Lee, a member of PURE’s Board of Directors and its largest shareholder. The f...
Source: Business Wire
Date: July, 02 2018 08:36
PURE Bioscience, Inc. (PURE) CEO Hank Lambert on Q3 2018 Results - Earnings Call Transcript
PURE Bioscience, Inc. (PURE) Q3 2018 Earnings Conference Call June 13, 2018 04:30 PM ET Executives Terri MacInnis - VP of Investor Relations, Bibicoff & MacInnis Inc Hank Lambert - Chief Executive Officer Mark Elliott - Vice President Finance Analysts Lauren Chung - Wes...
Source: SeekingAlpha
Date: June, 13 2018 20:09
PURE Bioscience Reports Fiscal 2018 Third Quarter and Nine-Month Financial Results
Update on PURE’s Food Safety Solutions Outlook for Calendar 2018 PURE Bioscience, Inc. ( OTCQB: PURE ) , creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period...
Source: Business Wire
Date: June, 13 2018 16:06
PURE Bioscience Sets Conference Call to Report 2018 Fiscal Third Quarter and Nine-Month Financial Results
Food Safety Solutions Update on PURE® Hard Surface and PURE Control® Antimicrobials PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on June 13, 2018 the Company will file its ...
Source: Business Wire
Date: May, 30 2018 08:36
PURE Bioscience Responds to the Latest Foodborne Illness Outbreak Tied to Romaine Lettuce
Use of FDA Approved PURE Control® Antimicrobial in Produce Processing Would Reduce Future Outbreak Risk PURE Bioscience, Inc. ( OTCQB: PURE ) , creator of the patented silver dihydrogen citrate ( SDC ) antimicrobial, today responded to the current widespread foodborn...
Source: Business Wire
Date: April, 26 2018 08:36
PURE Bioscience reports Q2 results
PURE Bioscience (NASDAQ: PURE ): Q2 EPS of -$0.03 Revenue of $0.41M (-8.9% Y/Y) Press Release More news on: PURE Bioscience, Earnings news and commentary, Energy stocks news, ,
Source: SeekingAlpha
Date: March, 14 2018 16:27
PURE Bioscience Reports Fiscal 2018 Second Quarter and Six-Month Financial Results
Update on PURE’s Food Safety Solutions Outlook for Calendar 2018 PURE Bioscience, Inc. ( OTCQB: PURE ) , creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period...
Source: Business Wire
Date: March, 14 2018 16:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.420.500.500.4297,402
2018-12-130.530.480.540.4836,135
2018-12-120.500.510.5270.5054,939
2018-12-110.510.510.510.5013,271
2018-12-100.490.510.5150.4926,893

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1428,68097,40229.4450Cover
2018-12-1313,69536,13537.8995Short
2018-12-1223,11454,93942.0721Short
2018-12-1110,14013,27176.4072Short
2018-12-1025,78826,89395.8911Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PURE.


About PURE Bioscience (OTC: PURE)

Logo for PURE Bioscience (OTC: PURE)

lt p gt PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad spectrum, non toxic antimicrobial agent, which offers hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California San Diego metropolitan area . Additional information on PURE is available at www.purebio.com lt /p gt

 

Contact Information

 

 

Current Management

  • Henry Lambert / CEO
  • Mark Elliott / VP, Fin., Principal Fin. Officer, Principal Acct. Officer
    • Mr. Elliott, , joined PURE Bioscience in and has been responsible for managing all accounting and regulatory reporting activities since he was promoted to Controller in May . He has also been responsible for establishing all current financial and reporting systems. Prior to joining the Company , Mr. Elliott worked in government accounting. He earned a Bachelor of Science, Business AdministrationAccountancy at California State UniversitySan Marcos.
  • David Pfanzelter / Chairman
  • Gary D. Cohee /
  • Elizabeth Hagan /
  • Tom Y. Lee /
  • William Otis /
  • Janet Risi / Compensation Committee Member
    • Ms. Risi currently serves as President and Chief Executive Officer of Independent Purchasing Cooperative IPC a supply chain management organization, which she founded in . IPC supplies all goods and services to the international fast food company, SUBWAY.. Risi formed IPC when SUBWAY had , restaurants, and has served on the SUBWAY Strategic Planning Council to help grow the brand to over , units worldwide. IPC now manages in excess of billion annually, covering food, packaging, equipment supplies, distribution, Gift and Loyalty card sales and marketing management, and services such as technology implementation. Prior to founding IPC, Ms. Risi was a commodities buyer for Ralston Purina. Ms. Risi also serves on the board of directors for Coral Gables Trust Bank and The Florida House. Ms. Risi received a B.A in English and a minor in Business from DePauw University.
  • David Theno /

Current Share Structure

  • Market Cap: $45,498,139 - 03/15/2018
  • Authorized: 100,000,000 - 03/15/2018
  • Issue and Outstanding: 67,907,670 - 03/15/2018

 


Recent Filings from (OTC: PURE)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 18 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: December, 29 2017
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: December, 29 2017
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: December, 20 2017
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: December, 20 2017

 

 


Daily Technical Chart for (OTC: PURE)

Daily Technical Chart for (OTC: PURE)


Stay tuned for daily updates and more on (OTC: PURE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PURE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PURE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PURE and does not buy, sell, or trade any shares of PURE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/